Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Biogen Inc.
DescriptionHuman mAb targeting alpha synuclein (SNCA)
Molecular Target Alpha synuclein (SNCA)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationParkinson's disease (PD)
Indication DetailsTreat Parkinson's disease (PD)
Regulatory Designation
PartnerNeurimmune Holding AG

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today